CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

被引：0

作者：

Jagannath, Sundar ^{[1
]}

Martin, Thomas ^{[2
]}

Usmani, Saad ^{[3
]}

Berdeja, Jesus ^{[4
]}

Jakubowiak, Andrzej ^{[5
]}

Agha, Mounzer ^{[6
]}

Cohen, Adam ^{[1
,7
]}

Deol, Abhinav ^{[8
]}

Htut, Myo ^{[9
]}

Lesokhin, Alexander ^{[3
]}

Munshi, Nikhil ^{[10
,11
]}

O'Donnell, Elizabeth ^{[12
]}

Jackson, Carolyn ^{[13
]}

Yeh, Tzu-Min ^{[13
]}

Banerjee, Arnob ^{[14
]}

Zudaire, Enrique ^{[14
]}

Madduri, Deepu ^{[13
]}

DelCorral, Christopher ^{[15
]}

Pacaud, Lida ^{[15
]}

Lin, Yi ^{[16
]}

机构：

[1] Mt Sinai Med Ctr, New York, NY USA

[2] Univ Calif San Francisco, San Francisco, CA USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Univ Chicago, Chicago, IL USA

[6] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[7] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

[8] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[9] City Hope Comprehens Canc Ctr, Duarte, CA USA

[10] Dana Farber Canc Inst, Boston, MA USA

[11] Harvard Med Sch, Vet Affairs Boston Healthcare Syst, Boston, MA 02115 USA

[12] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA

[13] Janssen Res & Dev, Raritan, NJ USA

[14] Janssen Res & Dev, Spring House, PA USA

[15] Legend Biotech USA Inc, Somerset, NJ USA

[16] Mayo Clin, Rochester, MN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-275

引用

页码：S187 / S187

页数：1

共 50 条

[41] Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Usmani, Saad Z.
Nahi, Hareth
Plesner, Torben
Weiss, Brendan M.
Bahlis, Nizar J.
Belch, Andrew
Voorhees, Peter M.
Laubach, Jacob P.
van de Donk, Niels W. C. J.
Ahmadi, Tahamtan
Uhlar, Clarissa M.
Wang, Jianping
Feng, Huaibao
Qi, Ming
Richardson, Paul G.
Lonial, Sagar
LANCET HAEMATOLOGY, 2020, 7 (06): : E447 - E455
[42] A phase 1b study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma
San-Miguel, J. F.
Richardson, P. G. G.
Sezer, O.
Guenther, A.
Siegel, D. S. D.
Blade, J.
LeBlanc, R.
Sutherland, H. J.
Mateos, M.
Gramatzki, M.
Hazell, K. M.
Bengoudifa, B.
Bourquelot, P. M.
Anderson, K. C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[43] Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)
Van De Donk, Niels W. C. J.
Sidana, Surbhi
Schecter, Jordan M.
Jackson, Carolyn Chang
Lendvai, Nikoletta
De Braganca, Kevin C.
Slaughter, Ana
Lonardi, Carolina
Vlummens, Philip
Varsos, Helen
Corsale, Christina
Madduri, Deepu
Jadidi, Shirin
Gu, Junchen
Zhao, Hao
Li, Katherine
Lee, Erin
Marquez, Loreta
Zhao, Man
Yeh, Tzu-min
Chen, Diana
Florendo, Erika
Patel, Nitin
Akram, Muhammad
Perez-Larraya, Jaime Gellego
Rodriguez Otero, Paula
BLOOD, 2023, 142
[44] Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Weisel, Katja
Martin, Thomas
Krishnan, Amrita
Jagannath, Sundar
Londhe, Anil
Nair, Sandhya
Diels, Joris
Vogel, Martin
Schecter, Jordan M.
Banerjee, Arnob
Berdeja, Jesus G.
Nesheiwat, Tonia
Garrett, Ashraf
Qi, Keqin
Valluri, Satish
Usmani, Saad Z.
Yong, Kwee
CLINICAL DRUG INVESTIGATION, 2022, 42 (01) : 29 - 41
[45] Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice
Delforge, Michel
Vekemans, Marie-Christiane
Depaus, Julien
Meuleman, Nathalie
Van de Velde, Ann
Vande Broek, Isabelle
Vandervennet, Sophie
Van Hoorenbeeck, Sandra
Moorkens, Evelien
Strens, Danielle
Diels, Joris
Ghilotti, Francesca
Haefliger, Benjamin
Dalhuisen, Sander
Deraedt, William
Anguille, Sebastien
HEMASPHERE, 2022, 6 (12):
[46] Final results for the 1703 phase 1b/2 study of Elotuzumab (Elo) in combination with Lenalidomide (Len) and dexamethasone (dex) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Raab, M. S.
Richardson, P. G.
Jagannath, S.
Moreau, P.
Jakubowiak, A. J.
Facon, T.
Vij, R.
White, D.
Reece, D. E.
Benboubker, L.
Zonder, J.
Tsao, L. C.
Anderson, K. C.
Bleickardt, E.
Singhal, A. K.
Lonial, S.
Oncology Research and Treatment, 2015, 38 : 165 - 165
[47] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
Biran, Noa
Siegel, David
Berdeja, Jesus G.
Raje, Noopur
Cornell, Robert Frank
Alsina, Melissa
Kovacsovics, Tibor
Fang, Belle
Kimball, Amy S.
Landgren, Ola
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
[48] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Mikhael, Joseph
Richardson, Paul
Usmani, Saad Z.
Raje, Noopur
Bensinger, William
Karanes, Chatchada
Campana, Frank
Kanagavel, Dheepak
Dubin, Franck
Liu, Qianying
Semiond, Dorothee
Anderson, Kenneth
BLOOD, 2019, 134 (02) : 123 - 133
[49] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Martin, Thomas
Baz, Rachid
Benson, Don M.
Lendvai, Nikoletta
Wolf, Jeffrey
Munster, Pamela
Lesokhin, Alexander M.
Wack, Claudine
Charpentier, Eric
Campana, Frank
Vij, Ravi
BLOOD, 2017, 129 (25) : 3294 - 3303
[50] PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Moreau, P.
Chanan-Khan, A.
Roberts, A. W.
Agarwal, A.
Facon, T.
Kumar, S.
Touzeau, C.
Diehl, S.
Cordero, J.
Ross, J.
Munasinghe, W.
Zhu, M.
Salem, A. H.
Leverson, J.
Maciag, P.
Verdugo, M.
Harrison, S. J.
HAEMATOLOGICA, 2016, 101 : 81 - 82

← 1 2 3 4 5 →